In a new judgment that further explores the application of competition law to intellectual property rights, the EU General Court has upheld a 2005 Commission decision finding that AstraZeneca1 abused a marketdominant position by blocking or delaying the entry of generic versions of its ulcer drug Losec2.  However, the Court has also reduced to €52.5 million the €60 million fine originally imposed on AstraZeneca, reflecting the Commission’s failure to prove one element of its case.

To read this complete article visit IP Frontline.
Downloads –